Drug firms and regulatory agencies must consider how drugs are usedBMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a2083 (Published 14 October 2008) Cite this as: BMJ 2008;337:a2083
- Lisa Hitchen
Safety experts have criticised drug regulators and the drug industry for not doing enough to ensure that packaging and labelling of products is safe.
Both concentrate on the efficacy and safety of the drug or device, but do not look at how it is used in practice, Liz Kay, clinical director of pharmacy for Leeds Teaching Hospitals NHS Trust, told the BMJ at a seminar on delivering safer intravenous drugs in Birmingham last week.
“The practical use of medicines is not high enough priority. Not enough emphasis is given to how the drug is used in a healthcare setting and how it is used by the patient,” she said.
The seminar focused on the National Patient Safety Agency’s patient safety alert on injectable drugs, issued …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial